U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 1 - 10 of 24 results

structurally diverse
Status:
US Approved Rx (2007)
Source:
BLA125158
(2007)
Source URL:
First approved in 2007
Source:
BLA125158
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
INN:bavebegene tovacivec [INN]
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
INN:rilimogene glafolivec [INN]
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
INN:rilimogene galvacirepvec [INN]
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
INN:raxorulimogene belzovacirepvec [INN]
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
INN:mesmulogene ancovacivec [INN]
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
INN:tipapkinogene sovacivec [INN]
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT03294083: Phase 1/Phase 2 Interventional Active, not recruiting Renal Cell Carcinoma
(2018)
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT02759588: Phase 1/Phase 2 Interventional Completed Ovarian Cancer
(2016)
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT03493945: Phase 1/Phase 2 Interventional Completed Metastatic Prostate Cancer
(2018)
Source URL:

Class:
STRUCTURALLY DIVERSE